Los Angeles, CA - 
(NewMediaWire) - April 6, 2021 - The Schall Law Firm, a
national shareholder rights litigation firm, reminds investors of a class
action lawsuit against Aquestive Therapeutics, Inc. (“Aquestive” or “the
Company”) (NASDAQ: AQST) for violations of
§§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5
promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the
Company's securities between December 2, 2019 and September 25, 2020, inclusive
(the ''Class Period''), are encouraged to contact the firm before April 30,
2021.
If you are a shareholder who
suffered a loss, click here to participate.
We also encourage you to contact
Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los
Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You
can also reach us through the firm's website at www.schallfirm.com,
or by email at brian@schallfirm.com.
The class, in this case, has not
yet been certified, and until certification occurs, you are not represented by
an attorney. If you choose to take no action, you can remain an absent class
member.
According to the Complaint, the
Company made false and misleading statements to the market. Aquestive included
data in its New Drug Application (“NDA”) submission for Libervant Buccal Film
for the management of seizure clusters (“Libervant”) that showed a suboptimal
drug exposure level for certain weight groups. This inappropriate data lowered
the likelihood of the NDA achieving approval. Based on these facts, the
Company’s public statements were false and materially misleading throughout the
class period. When the market learned the truth about Aquestive, investors
suffered damages.
Join the case to
recover your losses.
The Schall Law Firm represents
investors around the world and specializes in securities class action lawsuits
and shareholder rights litigation.
This press release may be
considered Attorney Advertising in some jurisdictions under the applicable law
and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
SOURCE:
The Schall Law Firm
